Currently out of the existing stock ratings of Jonathan Sakraida, 8 are a HOLD (57.14%), 4 are a BUY (28.57%), 2 are a SELL (14.29%).

Jonathan Sakraida

Work Performance Price Targets & Ratings Chart

Analyst Jonathan Sakraida, carries an average stock price target met ratio of 80% that have a potential upside of 7.99% achieved within 76 days. Previously, Jonathan Sakraida worked at CFRA.

Jonathan Sakraida’s has documented 27 price targets and ratings displayed on 11 stocks. The coverage was on Industrials, Healthcare sectors.

Most recent stock forecast was given on VRT, Vertiv Holdings Co at 06-Oct-2025.

Wall Street Analyst Jonathan Sakraida

Analyst best performing recommendations are on CMI (CUMMINS).
The best stock recommendation documented was for CMI (CUMMINS) at 8/12/2025. The price target of $400 was fulfilled within 1 day with a profit of $6 (1.52%) receiving and performance score of 15.23.

Average potential price target upside

CMI Cummins IR Ingersoll Rand ITW Illinois Tool Works MMM 3M Company PH Parker-Hannifin PNR Pentair PLC PNT POINT Biopharma Global SNA Snap-On SWK Stanley Black & Decker VRT Vertiv Holdings Co WAT Waters

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 18-Dec-2025

$901

$225.05 (33.29%)

$730

10 days ago
(02-Jul-2026)

40/42 (95.24%)

$239.3 (36.16%)

503

Buy Since 14-Nov-2025

$874

$188.13 (27.43%)

$794

25 days ago
(17-Jun-2026)

16/18 (88.89%)

$156.22 (21.76%)

618

Hold Since 08-Jun-2026

$850

$164.13 (23.93%)

$500

1 months 4 days ago
(08-Jun-2026)

16/18 (88.89%)

$177.32 (26.36%)

185

Buy Since 09-Feb-2026

$745

$59.13 (8.62%)

$675

1 months 16 days ago
(26-May-2026)

33/34 (97.06%)

$76.25 (11.40%)

666

Buy Since 23-Jan-2026

$760

$74.13 (10.81%)

$610

2 months 5 days ago
(07-May-2026)

9/10 (90%)

$77.12 (11.29%)

261

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Jonathan Sakraida?

On 2023

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?